Literature DB >> 22443981

Approach to and treatment of differentiated thyroid carcinoma.

Furio Pacini1, Maria Grazia Castagna.   

Abstract

Thyroid cancer is the most common endocrine malignancy, although representing fewer than 1% of all human tumors. Differentiated thyroid carcinoma (DTC) includes the papillary and follicular histotypes and their variants, accounting for more than 90% of all thyroid cancers. Given the changing presentation of DTC in the last years, the aim of DTC management is to ensure the most effective but least invasive treatment, and adequate follow-up for a disease that nowadays is mostly cured just with surgery and is rarely fatal. This review addresses the multiple steps of current management, based on previous assumptions. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22443981     DOI: 10.1016/j.mcna.2012.01.002

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  22 in total

Review 1.  Treatment strategies for radioactive iodine-refractory differentiated thyroid cancer.

Authors:  Francis Worden
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Stefania Camastra; Ugo Politti; Ilaria Ruffilli; Roberto Vita; Giuseppe Navarra; Salvatore Benvenga; Alessandro Antonelli
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

Review 3.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

4.  Ultrasound predictors of malignancy in indeterminate thyroid nodules.

Authors:  M-L Matthey-Gie; S M Walsh; A C O'Neill; A Lowery; D Evoy; D Gibbons; R S Prichard; S Skehan; E W McDermott
Journal:  Ir J Med Sci       Date:  2014-01-09       Impact factor: 1.568

Review 5.  The association between BRAF (V600E) mutation and pathological features in PTC.

Authors:  Xin Liu; Kangkang Yan; Xuejun Lin; Longyu Zhao; Wenxiu An; Chunpeng Wang; Xiaodong Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-04       Impact factor: 2.503

6.  Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.

Authors:  Jiao Li; Jun Liang; Teng Zhao; Yansong Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-16       Impact factor: 9.236

7.  Comparison between liquid and tablet levothyroxine formulations in patients treated through enteral feeding tube.

Authors:  I Pirola; L Daffini; E Gandossi; D Lombardi; A Formenti; M Castellano; C Cappelli
Journal:  J Endocrinol Invest       Date:  2014-05-01       Impact factor: 4.256

8.  Reconstruction using a frozen tumor-bearing vertebra in total en bloc spondylectomy can enhance antitumor immunity.

Authors:  Hideki Murakami; Satoshi Kato; Yasuhiro Ueda; Yoshiyasu Fujimaki; Hiroyuki Tsuchiya
Journal:  Eur Spine J       Date:  2013-10-05       Impact factor: 3.134

9.  Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype.

Authors:  Ryan J Ellis; Yonghong Wang; Holly S Stevenson; Myriem Boufraqech; Dhaval Patel; Naris Nilubol; Sean Davis; Daniel C Edelman; Maria J Merino; Mei He; Lisa Zhang; Paul S Meltzer; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

Review 10.  [Current treatment strategies for papillary thyroid microcarcinoma].

Authors:  J Plzák; J Astl; G Psychogios; J Zenk; P Laštůvka; J Betka
Journal:  HNO       Date:  2013-04       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.